Open Investment Opportunities

We carefully select every company we support, investing in a maximum of 4 projects a year.

bt_bb_section_bottom_section_coverage_image

We invite investors and their professional advisers

We carefully select every company we support, investing in a maximum of 4 projects a year.

You will have access to Member events where we will showcase new investments, provide the opportunity to meet the management teams and network with like-minded individuals.

There is no joining fee or obligation to invest.

Professional advisors join as Corporate Members and will enjoy the same benefits as Investor Members.

https://www.norcliffe.capital/wp-content/uploads/2020/08/image_illustrations_01.png

Open Investment Opportunities

Aureum Diagnostics

Total Fundraise: £5 million
Available Investment: £800,000 | Available until end of May 2025
Status: Open
Tell me more

Established in 2021, Aureum Diagnostics is revolutionising the diagnostic landscape. The company focuses on developing high-performance, low-cost electrochemical biosensing platforms for the $50 billion point of care medical diagnostics market and the $4.9 billion biosafety testing market. Aureum Diagnostics offers a measurement platform that includes a low-cost handheld connected instrument and very affordable single-use disposable test strips. Their tests are as simple and inexpensive as traditional lateral flow tests, yet as accurate as PCR tests, allowing for the detection of multiple biomarkers from a single sample.

With exciting commercial partnerships with Merck and ElectraDx, Aureum has successfully completed a sale of intellectual property worth approximately $50 million and has a revenue-generating strategic co-development partnership with Merck. Designed to surpass current and emerging competitors, AureumDX’s diagnostics platforms are truly state-of-the-art.

SMi Systems

Total Fundraise: £5 million
Available Investment: £600,000 | Available until end of May 2025
Status: Open
Tell me more

SMi Systems are revolutionising the field of molecular science. Their technology can visualise single molecules and directly measure their interactions, allowing for hundreds of tests on thousands of samples in just milliseconds per sample. This ability to observe individual molecules provides undeniable proof of their existence and enables highly accurate quantification, marking a groundbreaking advancement in biomedical research.

This innovative technology was made possible by Nobel Prize-winning contributions in 2014 and 2017. SMi’s platform will cater to both drug discovery and diagnostic sectors, replacing outdated technologies such as PCR, PSR, and ELISA tests that currently dominate an $11 billion market. Development of SMi’s platform is complete, and it will be available for the research market in early 2025, with a full launch planned for late 2025.

Laverock Therapeutics
laverock logov

Total Fundraise: £8 million
Available Investment: £2.2 million | Available until end of May 2025
Status: Open
Tell me more

Laverock Therapeutics is a gene silencing company that utilises a powerful technology to harness the body’s natural gene regulatory mechanisms. Their goal is to develop a new generation of programmable advanced therapies that are more effective, safer, and more accessible for treating major diseases.

Laverock Therapeutics stands out as one of the most innovative companies in the field of gene therapy. They have developed a novel approach to controlling gene expression that has garnered attention from major pharmaceutical companies, including E. Lilly. Their technology allows for the precise tuning of gene expression, similar to adjusting the volume on a radio, rather than simply turning a gene on or off as current technologies do. This innovative approach has numerous potential applications, with their initial focus on enhancing the latest generation of cancer immunotherapies. Later, they aim to provide “off-the-shelf” cellular therapies for treating diabetes.

4D Medicine

Total Fundraise: £4 million
Available Investment: £2 million | Available until end of June 2025
Status: Open
Tell me more

4D Medicines has developed a unique, biodegradable polymer that can be 3D printed to create a variety of implantable devices for orthopedic repairs, nerve repairs, slow drug release, and cosmetic dermal fillers. They anticipate receiving their first regulatory approval this year. The company has already turned down an earn-out acquisition offer of £38 million based solely on the value of the biopolymer, as they firmly believe they can generate greater value by developing their own applications.

4D Medicines is on a mission to revolutionise biomaterials for the medical device market, enhancing patient outcomes through powerful collaborations with dynamic industry partners. By harnessing their unique materials and expertise in resorbable device design, they will team up with established and emerging market players, paving the way for the next generation of implantable resorbable devices across a wide array of medical applications.

Santersus

Total Fundraise: £8 million
Available Investment: £2 million | Available until end of September 2025
Status: Open
Tell me more

Santersus has developed a revolutionary blood purification technique aimed at treating sepsis, autoimmune conditions, and transplanted organs, with potential applications in cancer and Alzheimer’s disease as well. In the past 15 years, it has been discovered that products from white blood cells known as NETs can initiate or worsen these conditions. Santersus’s patented technology effectively removes NETs from the blood using a standard apheresis system.

Santersus has already conducted a First-in-Human trial for treating sepsis, which accounts for 20% of deaths worldwide, and the results have been excellent. They have also received FDA breakthrough status for their NucleoCapture® device. Commercial partnerships have been established with OrganOx to improve transplant organ treatment and with Inus Health to conduct trials for Alzheimer’s disease.

With a world-class team that has a proven track record in generating significant returns, the simplicity and scalability of this system make it suitable for a mass market. The design allows it to be connected to standard plasma separation devices. Terumo, with a market cap of $26 billion, is a global leader in apheresis systems and is collaborating with Santersus as both an investor and partner. This technology has the potential to save millions of lives, and we believe it will also offer exceptional value, making it an outstanding addition to our portfolio.

Aureum Diagnostics

Aureum Diagnostics

Sector: MedTech
Total Fundraise: £3.51 million
Available Investment: £700,000
Status: Open
Tell me more

Medical diagnosis is about to undergo a revolution based on the next generation of cheap, mass manufacturable, electrochemical sensors like those to check blood sugar levels in people with diabetes. Aureum Diagnostics is a spin-out company from the world-leading Innovation Centre at the University of Strathclyde and is based on the work of Dr Corrigan and his team.

The team have already demonstrated the ability of their electrochemical platform to detect COVID in 2 minutes and to detect critical markers of sepsis, where a one hour delay in diagnosis can result in a 10% increase in mortality. The platform is ideally suited for rapid diagnosis of many conditions at the point of care and for the rapid diagnosis of COVID in sites like travel hubs, schools, workplaces and at home.

The Company requires £3.51 million for a total investor shareholding of 75.6% of the Company, at a pre-money valuation of £1.13 million to develop two types of readers: highly sensitive impedimetric readers and cheaper amperometric readers which use similar technology to glucose monitoring strips. Potential investor returns are 7x to 15x.

SMi Drug Discovery

Sector: MedTech
Total Fundraise: £3.64 million
Available Investment: £800,000
Status: Open
Tell me more

SMi Drug Discovery has developed a transformational, new, optical technology that will have far-reaching benefits in the fields of diagnosis and drug discovery. SMi’s technology is a variant of super resolution microscopy, an area which was the subject of Nobel Prizes in 2014 and 2017. SMi have been awarded a non-dilutive £1.9M UK Innovation grant for the development of their platform for virus diagnosis in large central laboratories.

The system can identify and count individual virus in a sample in 50 milliseconds, with a sensitivity equivalent to the gold standard PCR tests. SMi’s technology complements Aurem’s in that is designed for large central locations.

SMi’s platform’s second application is in speeding up drug discovery where cutting a year off development can save > $100 million. During drug development, scientists need to know how a drug binds to its target, exactly where and for how long. SMi’s technology is revolutionary as it can visualise hundreds of thousands of these interactions whereas current techniques provide only average data. A good analogy is that current techniques are like trying to determine the exact composition of traffic from the noise of vehicles whereas, SMi’s technology photographs and counts every bus, car, lorry and bike.

The Company is raising £3.64 million for 39.6% equity, at a pre-money valuation of £4 million. Potential investor returns are 8x to 16x.

COMING SOON

Aureum Diagnostics

Aureum Diagnostics

Medical diagnosis is about to undergo a revolution based on the next generation of cheap, mass manufacturable, electrochemical sensors like those to check blood sugar levels in people with diabetes. Aureum Diagnostics is a spin-out company from the world-leading Innovation Centre at the University of Strathclyde and is based on the work of Dr Corrigan and his team.